Cafepharma Daily Premium (On-Demand) Archive for October, 2018

Click a link below to view the mailing archive as if it had been sent to you.

2018-10-31 19:20		CP Wednesday Evening Premium: mgen earnings, Novartis Humira biosim, and more
2018-10-31 12:41		CP Wednesday Premium: More good news for Keytruda
2018-10-30 23:30		CP Tuesday Evening Premium: Pfizer may raise prices in January
2018-10-30 15:50		CP Tuesday Premium: Doctors are keeping an eye on reps
2018-10-29 23:41		CP Monday Evening Premium
2018-10-29 12:33		CP Monday Premium: Novartis and Pfizer team up to fight NASH
2018-10-28 20:02		CP Sunday Premium
2018-10-27 12:21		CP Saturday Premium: Upcoming biotech earnings
2018-10-27 00:40		CP Friday Evening Premium: Medical Device Makers Shut Out Of Value-Based Care
2018-10-26 12:41		CP Friday Premium: Pfizer works to get doctors on board with Ibrance
2018-10-26 00:01		CP Thursday Evening Premium: Big Pharma earnings
2018-10-25 12:37		CP Thursday Premium: JNJ's new vaccine plant
2018-10-25 00:10		CP Wednesday Evening Premium: Amgen cuts Repatha price
2018-10-24 14:49		CP Wednesday Premium: FDA approves first new flu drug in almost 20 years
2018-10-23 23:16		CP Tuesday Evening Premium: Precision medicine
2018-10-23 17:49		CP Tuesday Premium: Pfizer and Bain Capital create a company
2018-10-22 23:21		CP Monday Evening Premium: More news from ESMO
2018-10-22 13:37		CP Monday Premium: Bristol's Opdivo approval date pushed back
2018-10-21 23:45		CP Sunday Premium
2018-10-20 23:21		CP Saturday Premium
2018-10-19 22:47		CP Friday Premium
2018-10-18 23:57		CP Thursday Evening Premium: Genome synthesis
2018-10-18 13:57		CP Thursday Premium: Novartis is acquiring; Pfizer is cutting
2018-10-18 00:39		CP Wednesday Evening Premium: New eye health companies and microbiome news
2018-10-17 12:53		CP Wednesday Premium: AbbVie gets priority review for blood cancer combo
2018-10-16 23:59		CP Tuesday Evening Premium: Pharma's political contributions
2018-10-16 12:55		CP Tuesday Premium: Upcoming FDA decisions
2018-10-16 00:00		CP Monday Evening Premium: AI, Big Data and drug discovery
2018-10-15 13:50		CP Monday Premium: Q3 pharma earnings coming up
2018-10-14 23:08		CP Sunday Premium
2018-10-13 23:03		CP Saturday Premium
2018-10-12 23:49		CP Friday Evening Premium: AcelRx gets panel support
2018-10-12 13:59		CP Friday Premium: Merck ditches Lantus biosim
2018-10-11 23:27		CP Thursday Evening Premium: what's behind the pharma M&A push
2018-10-11 13:47		CP Thursday Premium: Will 27-45 year olds get the HPV shot?
2018-10-10 23:01		CP Wednesday Evening Premium: Celltrion and Teva get unanimous yes from FDA panel
2018-10-10 13:42		CP Wednesday Premium: Trump to sign biosimilar bill
2018-10-09 23:37		CP Tuesday Premium: Glympse Raises $22M
2018-10-09 12:46		CP Tuesday Premium: FDA gives favorable review of Rituxan biosim ahead of panel
2018-10-08 23:44		CP Monday Evening Premium: Acacia anticipates 2019 PONV med launch
2018-10-08 13:00		CP Monday Premium: GSK helping UK startup Sitryx
2018-10-07 23:27		CP Sunday Premium
2018-10-06 12:59		CP Saturday Premium
2018-10-05 21:45		CP Friday Evening Premium: Another hATTR drug approved
2018-10-05 12:59		CP Friday Premium: European biotech funding may hit record
2018-10-04 23:56		CP Thursday Evening Premium
2018-10-04 12:50		CP Thursday Premium - Critics want more justification of the Takeda-Shire buy
2018-10-04 00:39		CP Wednesday Evening Premium - Sarepta's gene therapy for DMD
2018-10-03 13:23		CP Wednesday Premium - GSK rolls back the calendar on doctor payments
2018-10-02 23:04		CP Tuesday Evening Premium - Gilead's latest NASH treatment candidate
2018-10-02 13:12		CP Tuesday Premium - GO Therapeutics in license deal with Roche
2018-10-01 22:42		CP Monday Evening Premium - Canada agrees to 10 years exclusivity for biologics
2018-10-01 13:44		CP Monday Premium - Pfizer CEO Read is stepping down
2018-10-01 13:25		CP Weekend Premium: Please pardon our technical difficulties

<< Archive Index • Subscribe >>

Cafepharma Daily Premium (On-Demand) Archive for October, 2018

Contact Us

Past Issues

Unsubscribe